ArticleClinical Medicine Insights. Cardiology2025
Evaluating the Safety and Efficacy of SGLT-2 Inhibitors on Reducing Cardiovascular and Renal Mortality, Morbidity and Inflammatory Outcomes in Various Patient Populations: A Systematic Review and Meta-Analysis of 92 920 Patients.
Article in Clinical Medicine Insights. Cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Impact of SGLT2 Inhibitors on Mortality Across Different Populations: A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2026Pooled it
- Safety and clinical impact of SGLT2 inhibitor in patients undergoing peritoneal dialysis: a target-trial emulation study.Clinical kidney journal · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The effect of Sodium Glucose Co-Transporter 2 inhibitors on cardiovascular, renal, dyslipidemia, and inflammatory markers has not been analyzed simultaneously. The goal is to determine if SGLT2 inhibitors significantly reduce cardiovascular and renal mortality, and improve these health outcomes. Methods: PubMed, Cochrane Library and MEDLINE databases were used to conduct a comprehensive literature search from inception to September 2023. Randomized control trials with follow-up for at least 8 weeks, with a group taking SGLT2 inhibitors being compared with a group taking either placebo or other medication, in which cardiovascular outcomes, renal outcomes, lipid biomarkers, and inflammatory markers were reported as the primary outcomes were included. The statistical analyses were conducted using Review Manager with a random-effects model. Results: Thirteen studies comprising 92 920 patients were analyzed for several outcomes. The analysis revealed a significant reduction in overall mortality, death due to heart failure, cardiovascular causes, and renal causes in the SGLT2 inhibitor group as compared to placebo. Pooled results also revealed a significant reduction in the frequency of renal replacement therapy and renal composite endpoint in patients on SGLT2 inhibitors. There was also a significant reduction in IL-6, TNF-a, systolic blood pressure in the same group. On the other hand, Flow Mediated Dilation (FMD), lipid profile, and the incidence of amputations and fractures showed no significant associated SGLT2 inhibitor therapy. Conclusion: Our analysis indicates that diabetics and non-diabetics suffering from cardiovascular and renal diseases experience a significant reduction in morbidity and mortality from SGLT2 inhibitor therapy, leading to a better prognosis of such conditions in the long-term.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.